Malaria Positivity Following a Single Oral Dose of Azithromycin Among Children in Burkina Faso: A Randomized Controlled Trial

Jessica Brogdon  
University of California, San Francisco

Clarisse Dah  
Centre de Recherche en Santé de Nouna

Ali Sié  
Centre de Recherche en Santé de Nouna

Mamadou Bountogo  
Centre de Recherche en Santé de Nouna

Boubacar Coulibaly  
Centre de Recherche en Santé de Nouna

Idrissa Kouanda  
Centre de Recherche en Santé de Nouna

Mamadou Ouattara  
Centre de Recherche en Santé de Nouna

Guillaume Compaoré  
Centre de Recherche en Santé de Nouna

Eric Nebie  
Centre de Recherche en Santé de Nouna

Mariam Seynou  
Centre de Recherche en Santé de Nouna

Elodie Lebas  
University of California, San Francisco

Fanice Nyatigo  
University of California, San Francisco

Huiyu Hu  
University of California, San Francisco

Benjamin F. Arnold  
University of California, San Francisco

Thomas M. Lietman  
University of California, San Francisco

Catherine E. Oldenburg  (catherine.oldenburg@ucsf.edu)
Abstract

Background. Azithromycin is a broad-spectrum antibiotic that has moderate antimalarial activity and has been shown to reduce all-cause mortality when biannually administered to children under five in high mortality settings in sub-Saharan Africa. One potential mechanism for this observed reduction in mortality is via a reduction in malaria transmission.

Methods. We evaluated whether a single oral dose of azithromycin reduces malaria positivity by rapid diagnostic test (RDT). We conducted an individually randomized placebo-controlled trial in Burkina Faso during the high malaria transmission season in August 2020. Children aged 8 days to 59 months old were randomized to a single oral dose of azithromycin (20 mg/kg) or matching placebo. At baseline and 14 days following treatment, we administered a rapid diagnostic test (RDT) to detect *Plasmodium falciparum* and measured tympanic temperature for all children. Caregiver-reported adverse events and clinic visits were recorded at the day 14 visit.

Results. We enrolled 449 children with 221 randomized to azithromycin and 228 to placebo. The median age was 32 months and 48% were female. A total of 8% of children had a positive RDT for malaria at baseline and 11% had a fever (tympanic temperature ≥37.5°C). In the azithromycin arm, 8% of children had a positive RDT for malaria at 14 days compared to 7% in the placebo arm (P=0.65). Fifteen percent of children in the azithromycin arm had a fever ≥37.5°C compared to 21% in the placebo arm (P=0.12). Caregivers of children in the azithromycin group had lower odds of reporting fever as an adverse event compared to children in the placebo group (OR 0.41, 95% CI 0.18-0.96, P=0.04). Caregiver-reported clinic visits were uncommon, and there were no observed differences between arms (P=0.32).

Conclusions. We did not find evidence that a single oral dose of azithromycin reduced malaria positivity during the high transmission season. Caregiver-reported fever occurred less often in children receiving azithromycin compared to placebo, indicating that azithromycin may have some effect on non-malarial infections.

Trial Registration: NCT03676751

Introduction

Children under 5 are the most vulnerable age group affected by malaria, accounting for 67% of all malaria deaths in 2019.(1) The malaria burden is often greatest during the first few years of life, before natural immunity is acquired.(2) Interventions such as seasonal malaria chemoprevention (SMC) have reduced deaths from severe malaria, but growing resistance to first line antimalarial drugs threatens to impede progress.(3, 4) Azithromycin (AZ) is a macrolide with modest anti-malarial properties that has been shown to have a negative impact on the asexual stages of the *Plasmodium falciparum* parasite.(5) While azithromycin is not widely used for malaria control, mass biannual azithromycin distribution has been shown to reduce all-cause child mortality and malaria parasitemia among preschool aged children in some settings. (6, 7)(8)
Burkina Faso is hyperendemic for malaria with more than 20 million people at risk.\(^{(9)}\) The Burkinabé Ministry of Health estimates that 66% of all deaths in children under 5 were attributable to malaria in 2018.\(^{(10)}\) Here we investigate changes in malaria positivity determined by rapid diagnostic test (RDT) among Burkinabé children 8 days to 59 months old who were individually randomized to receive a single dose of azithromycin or placebo. We hypothesized that children receiving azithromycin would have lower RDT positivity after a 14-day period compared to those receiving placebo.

**Methods**

**Study Overview.** This study was a placebo-controlled individually randomized trial evaluating a single oral dose of azithromycin (20 mg/kg) compared to placebo for malaria among children under 5. We conducted assessments at baseline and 14 days following enrollment. We also collected stool samples from the participants over a 6-month period, but these results will be reported separately. The trial was approved by the Comité National d’Ethique pour la Recherche (National Ethics Committee of Burkina Faso) in Ouagadougou, Burkina Faso and the Institutional Review Board at the University of California, San Francisco. Written informed consent was obtained from the caregiver prior to enrollment.

**Study Setting.** The trial was conducted in Nouna Town in northwestern Burkina Faso, which is approximately 300 kilometers from the capital city Ouagadougou. The Nouna population is peri-urban and consists almost exclusively of subsistence farmers. Children were enrolled in mid-August 2020 at the Nouna District Hospital. The primary endpoint occurred 2 weeks following enrollment in September 2020. In this setting malaria transmission is highly seasonal and typically peaks from July through October during the rainy season.\(^{(11)}\) Seasonal malaria chemoprophylaxis was administered concurrently to children aged 3–59 months on a monthly basis from July to October in Nouna town. The predominant malaria vector in the region is the *Anopheles gambiae* complex, and the *Anopheles coluzzi* species is most commonly found in Nouna.\(^{(12)}\) *P. falciparum* is the primary malaria species infecting humans in the region.\(^{(13)}\)

**Recruitment and Eligibility.** Mobilizers sensitized the community by visiting households with children under 5 based on the most recent census conducted by the Nouna Health and Demographic Surveillance Site (HDSS).\(^{(14)}\) Study staff informed caregivers about the study, and interested participants were encouraged to present to the Nouna District Hospital to be assessed for eligibility. Children meeting the following criteria were eligible for the study: age between 8 days and 59 months old, primary residence within Nouna town, available for the next 6-month period, no known allergy to macrolides, and able to orally feed (to swallow the study medication).

**Baseline Assessment.** At baseline, study staff conducted a survey with the caregiver. Questions included breastfeeding status, maternal age, the mother’s level of education, literacy, and gravidity. The study staff member utilized a custom mobile application to input all data into a handheld tablet (Dimagi, Inc., CommCare, 2020).
Malaria Assessment. An OnSite Pf/Pan antigen rapid test (CTK Biotech Inc, USA) was used to detect *Plasmodium falciparum* among participants at baseline and 14 days following treatment. Study staff measured tympanic temperature for all children at both study visits using the Braun Thermoscan 7 Digital Ear thermometer (Kaz, Inc., USA). Fever was defined as tympanic temperature $\geq 37.5^\circ$C. Febrile children and those with a positive malaria rapid diagnostic test (RDT) were referred for care.

Intervention. Enrolled participants were randomized to receive a single oral dose of azithromycin (20 mg/kg) or equivalent volume of matching placebo. The placebo was identical to the azithromycin in appearance and taste. Dosage was determined by height stick approximation if the child was able to stand or by weight if the child was under 12 months of age and/or unable to stand. The medication was administered as an oral suspension with a plastic dosing cup or syringe. All treatments were directly observed by the study team and recorded in the electronic mobile application.

Randomization. The randomization sequence was generated by the study statistician without blocking or stratifying in R. Unique participant identification numbers were created which were associated with the randomization assignment and uploaded into the electronic data capture platform. The trial was double masked and all field team members and participants were masked. The allocation concealment mechanism was a combination of the unique participant IDs and matching drug labels. The drug was labeled with 1 of 8 different letters to avoid the possibility of unmasking. After a participant ID was assigned to the child, the field team member scanned the ID into the electronic mobile application which then informed the team member which letter to treat the child with.

Follow-Up Assessment. Caregivers presented to the hospital 14 days after the baseline visit. A brief interview was conducted with the caregiver regarding any adverse events experienced by the child since treatment including abdominal pain, diarrhea, vomiting, constipation, or skin rash. These adverse events were specifically asked based on findings from previous pediatric azithromycin trials. Caregivers also reported if healthcare was sought for the child since treatment and the diagnosis (e.g. diarrhea, pneumonia, malaria).

Outcomes. The primary outcome for this trial was Shannon’s and Simpson’s diversity index of the gut microbiome at 6 months and will be reported separately. Secondary outcomes included malaria status at 14 days post enrollment determined by RDT, clinical malaria at 14 days post enrollment defined by a positive RDT and tympanic temperature $\geq 37.5^\circ$C, caregiver-reported adverse events, and clinic visits.

Sample size. The sample size was based on the primary outcome of the trial which was Shannon’s and Simpson’s diversity index of the gut microbiome. For the malaria outcome, we assumed 80% power to detect a significant effect with a sample size of 225 per arm, no loss to follow-up, and RDT positivity prevalence in the control group of 10%. Given these assumptions, the trial was powered to detect an absolute difference of 6.6%.

Statistical Methods. Descriptive baseline characteristics were summarized with proportions for categorical variables and medians and interquartile ranges (IQR) for continuous variables. The proportion
of participants with a fever (defined as tympanic temperature $\geq 37.5^\circ$C) at the time of the follow-up visit was calculated. We also calculated the proportion of children with a positive malaria RDT at the 14-day visit. Caregiver-reported health center visits were classified by arm and reason for the visit. Lastly, we calculated the proportion of children experiencing any adverse event as reported by their caregiver by study arm as well as each individual adverse event. Odds ratios (OR) and 95% confidence intervals (CI) were computed for each outcome using an unadjusted logistic regression model with the randomized treatment arm assigned as the predictor. Because RDTs can remain positive for several weeks even if there is no longer an active infection, we restricted the 14-day RDT model to children who were RDT negative at baseline as a sensitivity analysis. All analyses were intention-to-treat, where all randomized children were included regardless if they received their randomized assignment or not. Analyses were performed in Stata version 15.1 (StataCorp, College Station, TX).

Results

A total of 449 children were enrolled in the trial with 221 in the azithromycin arm and 228 in the placebo arm (Fig. 1). Baseline characteristics were balanced between groups (Table 1). The median age was 32 months for the azithromycin group and 32.5 for the placebo group. Three participants were under 1 month of age with the youngest being 32 days old. In both groups, 48% were female. Among the 449 children enrolled, 446 (99%) received their study treatment. At baseline, 10% of the children in the azithromycin group were RDT positive and 7% in the placebo group were RDT positive. Twenty-seven children total (6%) had a tympanic temperature $\geq 37.5^\circ$C at baseline. Two percent of participants in the azithromycin arm and 0.4% of participants in the placebo arm had a positive malaria RDT plus fever. Two children (1 per arm) were lost to follow-up (Fig. 1).

We did not find any evidence of a difference between the azithromycin and placebo arms for malaria or clinical outcomes at 14 days (Table 2). Malaria RDT positivity remained similar in the placebo group (7%) and azithromycin group (8%) (OR 1.17 for azithromycin vs placebo, 95% CI 0.58 to 2.37, $P = 0.65$). At the 14-day follow-up, 34 children (15%) in the azithromycin group had a tympanic temperature $\geq 37.5^\circ$C as well as 48 children (21%) in the placebo group. Three percent of children in both arms had a positive malaria RDT plus fever at 14 days. Caregivers of 3% of participants reported their child had a health center visit by the 14-day visit with no evidence of a difference between arms (2% azithromycin; 4% placebo, OR: 0.57, CI:0.19 to 1.72, $P = 0.32$). Diarrhea was the most common reason for a health center visit across both arms (OR 3.00 for azithromycin vs placebo, 95% CI 0.31 to 28.84, $P = 0.34$).

The results of the sensitivity analysis did not qualitatively change the results as we found no evidence of an effect of azithromycin on 14-day malaria RDT positivity in children with a negative RDT at baseline (OR 1.09 for azithromycin vs placebo, 95% CI 0.40 to 2.97, $P = 0.86$).

Overall, 10% of caregivers reported that their child experienced at least a single adverse event in the 14-day period after treatment with 18 in the azithromycin arm (8%) and 29 in the placebo arm (13%) (Table 3). Caregivers of children in the azithromycin arm had lower odds of reporting fever as an adverse
event compared to children in the placebo group (OR 0.41, 95% CI 0.18 to 0.96, \( P = 0.04 \)). Diarrhea was the most commonly reported adverse event with no difference between study arms (5% azithromycin; 8% placebo; OR 0.61, 95% CI 0.28 to 1.33, \( P = 0.21 \)). We did not observe evidence of a difference in any other adverse events.

**Discussion**

We did not find evidence that a single oral dose of azithromycin reduces malaria positivity within a 14-day period after treatment. One consideration is the coinciding seasonal malaria chemoprophylaxis (SMC) that was administered at the same time as the trial within the Nouna community. SMC distributions occurred monthly from July 13th -16th, August 12th -15th, September 11th -14th, and October 10th -13th. A trial in Burkina Faso and Mali found SMC + AZ provided additional protection from malaria, but this effect was limited to the first two weeks post-administration.\(^{(19)}\) Concomitant SMC distribution during the trial period may explain the lower than expected malaria prevalence we observed (8% RDT positivity at baseline and follow-up).\(^{(20–23)}\)

Community-level distribution of AZ could be more effective for malaria control compared to individual-level as several community based trials have demonstrated that mass AZ distribution reduces malaria parasitemia.\(^{20,23,24}\) For instance, a subset of villages in the MORDOR Niger trial reported that communities receiving azithromycin had half the odds of malaria parasitemia compared to communities treated with placebo.\(^{(7, 8)}\) Trachoma trials have also documented a reduction in malaria parasitemia following mass azithromycin distribution, although the evidence is mixed.\(^{(21, 23, 25–28)}\) Additionally, distributing AZ to communities may provide limited vector control as some studies suggest azithromycin decreases mosquito lifespan when ingested.\(^{(29)}\) While individual-level interventions may have some impact on malaria transmission, it is difficult to show a difference if the rate of reinfection is high, as during the peak transmission season. The present study did not collect serological data which could measure force of infection or measure the entomological inoculation rate (EIR). Community-level AZ interventions could have a greater impact on malaria transmission compared to individual-level interventions, but more research is needed.

We observed a lower probability of caregiver-reported fever in the azithromycin group compared to the placebo group, suggesting that azithromycin may have an effect on non-malaria fevers. Gastroenteritis and pneumonia were reduced 30% and 34% respectively in a West African azithromycin trial, suggesting AZ may lower other fever-inducing infections commonly found in sub Saharan Africa.\(^{(19, 22)}\) There were no other significant differences in other adverse events or clinic visits. Administration of azithromycin to preschool aged children appears to be safe and well tolerated.\(^{(16, 17)}\)

Limitations for this study include the sole use of an RDT rather than PCR or microscopy for defining malaria positivity. Some trials have documented low RDT sensitivity in this setting with results that may vary by parasite density.\(^{(30, 31)}\) RDTs generally perform worse with low parasite density infections, but due to the randomized nature of the study we do not expect any differential bias between study arms.\(^{(32)}\)
Future studies might consider performing more than one RDT test per individual where PCR capabilities are limited. Other limitations should be taken into consideration. Because the trial was designed and powered for a microbiome primary outcome, the trial was likely underpowered to detect differences for malaria specific outcomes. Azithromycin is rapidly absorbed and has a long half-life, but the 2-week duration of the study may have been too short to demonstrate significant effects. Lastly, this study took place in a peri-urban town that may not be generalizable to other communities. Nouna Town residents have access to health clinics and may have better health outcomes compared to more rural communities.

**Conclusion**

Azithromycin did not lower malaria positivity as measured by RDT within a 14-day period when administered as a single dose to children 1–59 months old. The point prevalence of fever was similar between the azithromycin and placebo groups, but caregiver-reported fever over the 14-day period from treatment occurred less often among children receiving azithromycin compared to placebo. We found no evidence that individual-level treatment with azithromycin affected malaria prevalence two weeks after treatment.

**Abbreviations**

**AZ**: Azithromycin  
**CI**: Confidence Interval  
**EIR**: Entomological Inoculation Rate  
**MDA**: Mass Drug Administration  
**OR**: Odds Ratio  
**SMC**: Seasonal Malaria Chemoprevention  
**RDT**: Rapid Diagnostic Test  
**USA**: United States of America

**Declarations**

**ACKNOWLEDGMENTS**

We thank the participants of the GAMIN II trial for their time and participation in the study. We also thank the research staff who collected the data for the trial.
**Funding.** This work was supported by the Bill and Melinda Gates Foundation (OPP1187628). Azithromycin and matching placebo were donated by Pfizer, Inc. The funders had no role in study design, data collection, analysis, decision to publish, or preparation of the manuscript.

**Availability of data and materials.** All data is publicly available on OSF ([www.osf.io](http://www.osf.io)).

**Contributions.** AS, CEO, and TL conceptualized and designed the trial. CD, MB, BC, MO, GC, EN, MS, and IK led the data collection with support from JB, EL, BA, and CEO. IK led the data management for the project with support from FN, HH, and BA. JB and CEO conducted the analyses, created the tables, and wrote the first draft of the manuscript. All authors contributed to the implementation of the study, interpretation, final revisions to the text, and approved the final version of the manuscript.

**ETHICS DECLARATIONS**

**Ethics approval and consent.** The study was reviewed by the Institutional Review Boards at the University of California, San Francisco and the National Ethics Committee of Burkina Faso. Written informed consent was obtained from the caregiver of the participant.

**Consent for publication.** Not applicable.

**Competing interests.** No conflicts of interest are reported. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

**RIGHTS AND PERMISSIONS**

**Open Access:** This work was supported, in whole or in part, by the Bill & Melinda Gates Foundation [OPP1187628]. Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/) or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

**References**

1. WHO. WHO World Malaria Report 2020. Malaria report 2020. 2020.

2. Rowe AK, Rowe SY, Snow RW, Korenromp EL, Armstrong Schellenberg JRM, Stein C, et al. The burden of malaria mortality among African children in the year 2000. International Journal of Epidemiology. 2006.

3. Baba E, Hamade P, Kivumbi H, Marasciulo M, Maxwell K, Moroso D, et al. Effectiveness of seasonal malaria chemoprevention at scale in west and central Africa: an observational study. Lancet. 2020;
4. Witkowski B, Berry A, Benoit-Vical F. Resistance to antimalarial compounds: Methods and applications. Drug Resist Updat. 2009;

5. Burns AL, Sleebs BE, Siddiqui G, De Paoli AE, Anderson D, Löffner B, et al. Retargeting azithromycin analogues to have dual-modality antimalarial activity. BMC Biol [Internet]. 2020 Sep 29 [cited 2021 May 28];18(1). Available from: https://pubmed.ncbi.nlm.nih.gov/32993629/

6. Oldenburg CE, Amza A, Cooley G, Kadri B, Nassirou B, Arnold BF, et al. Biannual versus annual mass azithromycin distribution and malaria seroepidemiology among preschool children in Niger: A sub-study of a cluster randomized trial. Malar J. 2019;

7. Keenan JD, Bailey RL, West SK, Arzika AM, Hart J, Weaver J, et al. Azithromycin to Reduce Childhood Mortality in Sub-Saharan Africa. N Engl J Med. 2018;

8. Arzika AM, Maliki R, Boubacar N, Kane S, Cotter SY, Lebas E, et al. Biannual mass azithromycin distributions and malaria parasitemia in pre-school children in Niger: A cluster-randomized, placebo-controlled trial. PLoS Med. 2019;

9. FY 2020 Burkina Faso Malaria Operational Plan [Internet]. [cited 2021 May 13]. Available from: www.pmi.gov

10. De M, Sante LA, Faso B. Avec l’appui de l’UNICEF.

11. Otte Im Kampe E, Müller O, Sie A, Becher H. Seasonal and temporal trends in all-cause and malaria mortality in rural Burkina Faso, 1998-2007. Malar J. 2015;

12. States Agency for International Development U. PMI VECTORLINK Burkina Faso Entomological Monitoring Annual Report, January—December 2019. 2019.

13. Tourre YM, Vignolles C, Viel C, Faruque FS, Malone JB. Malaria in Burkina Faso (West Africa) during the twenty-first century. [cited 2021 Jun 2]; Available from: https://doi.org/10.1007/s10661-019-7410-7

14. Sié A, Louis V, Gbangou A, Müller O, Niamba L, Stieglbauer G, et al. The Health and Demographic Surveillance System (HDSS) in Nouna, Burkina Faso, 1993–2007. Glob Health Action. 2010;

15. Basilion E V., Kilima PM, Mecaskey JW. Simplification and improvement of height-based azithromycin treatment for paediatric trachoma. Trans R Soc Trop Med Hyg. 2005;

16. Sié A, Dah C, Bountogo M, Ouattara M, Nebie E, Coulibaly B, et al. Adverse events and clinic visits following a single dose of oral azithromycin among preschool children: A randomized placebo-controlled trial. Am J Trop Med Hyg. 2021;

17. Oldenburg CE, Arzika AM, Maliki R, Kane MS, Lebas E, Ray KJ, et al. Safety of azithromycin in infants under six months of age in Niger: A community randomized trial. PLoS Negl Trop Dis [Internet].
2018 Nov 1 [cited 2021 May 27];12(11). Available from: https://pubmed.ncbi.nlm.nih.gov/30419040/

18. Ayele B, Gebre T, House JI, Zhou Z, McCulloch CE, Porco TC, et al. Adverse events after mass azithromycin treatments for trachoma in Ethiopia. Am J Trop Med Hyg [Internet]. 2011 Aug [cited 2021 May 27];85(2):291–4. Available from: /pmc/articles/PMC3144828/

19. Phiri MD, Cairns M, Zongo I, Nikiema F, Diarra M, Yerbanga RS, et al. The Duration of Protection from Azithromycin Against Malaria, Acute Respiratory, Gastrointestinal, and Skin Infections When Given Alongside Seasonal Malaria Chemoprevention: Secondary Analyses of Data from a Clinical Trial in Houndé, Burkina Faso, and Bou. Clin Infect Dis. 2021;

20. WHO. Burkina Faso World Malaria Report [Internet]. 2016 [cited 2021 May 14]. Available from: https://www.who.int/malaria/publications/country-profiles/2016/profile_bfa_en.pdf?ua=1

21. Schachterle SE, Mtove G, Levens JP, Clemens E, Shi L, Raj A, et al. Short-term malaria reduction by single-dose azithromycin during mass drug administration for trachoma, Tanzania. Emerg Infect Dis. 2014;

22. Chandramohan D, Dicko A, Zongo I, Sagara I, Cairns M, Kuepfer I, et al. Effect of Adding Azithromycin to Seasonal Malaria Chemoprevention. N Engl J Med. 2019;

23. Diallo A, Sié A, Sirima S, Sylla K, Ndiaye M, Bountogo M, et al. An epidemiological study to assess Plasmodium falciparum parasite prevalence and malaria control measures in Burkina Faso and Senegal. Malar J. 2017;

24. Gaynor BD, Amza A, Kadri B, Nassirou B, Lawan O, Maman L, et al. Impact of mass azithromycin distribution on malaria parasitemia during the low-transmission season in Niger: A cluster-randomized trial. Am J Trop Med Hyg [Internet]. 2014 [cited 2021 May 27];90(5):846–51. Available from: https://pubmed.ncbi.nlm.nih.gov/24615132/

25. Porco TC, Gebre T, Ayele B, House J, Keenan J, Zhou Z, et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: A randomized trial. JAMA - J Am Med Assoc [Internet]. 2009 Sep 2 [cited 2021 May 27];302(9):962–8. Available from: https://jamanetwork.com/

26. O'Brien KS, Cotter SY, Amza A, Kadri B, Nassirou B, Stoller NE, et al. Mass azithromycin and malaria parasitemia in Niger: Results from a community-randomized trial. Am J Trop Med Hyg [Internet]. 2017 [cited 2021 Jun 2];97(3):696–701. Available from: https://pubmed.ncbi.nlm.nih.gov/28722569/

27. Bloch EM, Munoz B, Mrango Z, Weaver J, Mboera LEG, Lietman TM, et al. The impact on malaria of biannual treatment with azithromycin in children age less than 5 years: A prospective study. Malar J [Internet]. 2019 Aug 23 [cited 2021 Jun 2];18(1). Available from: https://pubmed.ncbi.nlm.nih.gov/31443654/
28. Hart JD, Samikwa L, Sikina F, Kalua K, Keenan JD, Lietman TM, et al. Effects of Biannual Azithromycin Mass Drug Administration on Malaria in Malawian Children: A Cluster-Randomized Trial. Am J Trop Med Hyg [Internet]. 2020 Sep 1 [cited 2021 Jun 2];103(3):1329–34. Available from: https://pubmed.ncbi.nlm.nih.gov/32342841/

29. Gendrin M, Yerbanga RS, Ouedraogo JB, Lefèvre T, Cohuet A, Christophides GK. Differential effects of azithromycin, doxycycline, and cotrimoxazole in ingested blood on the vectorial capacity of malaria mosquitoes. Open Forum Infect Dis. 2016;

30. Tiono AB, Ouédraogo A, Diarra A, Coulibaly S, Soulama I, Konaté AT, et al. Lessons learned from the use of HRP-2 based rapid diagnostic test in community-wide screening and treatment of asymptomatic carriers of Plasmodium falciparum in Burkina Faso. Malar J. 2014;

31. Watson OJ, Sumner KM, Janko M, Goel V, Winskill P, Slater HC, et al. False-negative malaria rapid diagnostic test results and their impact on community-based malaria surveys in sub-Saharan Africa. BMJ Glob Heal. 2019;

32. Plucinski MM, Dimbu PR, Fortes F, Murphy SC, Smith NT, Cruz KR, et al. Malaria parasite density in individuals with different rapid diagnostic test results and concentrations of HRP2 antigen. Am J Trop Med Hyg. 2019;

33. Rapp RP. Pharmacokinetics and pharmacodynamics of intravenous and oral azithromycin: Enhanced tissue activity and minimal drug interactions. Annals of Pharmacotherapy. 1998.

Tables

Table 1. Baseline characteristics by treatment group

|                          | Azithromycin (N=221) | Placebo (N=228) |
|--------------------------|-----------------------|------------------|
| Child's age, months, median (IQR) | 32 (21 to 44)         | 32.5 (22 to 44.5) |
| Female sex, N (%)        | 107 (48%)             | 110 (48%)        |
| Currently breastfeeding, N (%) | 64 (29%)             | 51 (22%)         |
| Mother's age, years, median (IQR) | 26 (23 to 31)         | 27 (23 to 32)    |
| Mother is literate, N (%) | 92 (42%)              | 97 (43%)         |
| Positive malaria RDT    | 22 (10%)              | 15 (7%)          |
| Fever¹ N (%)            | 27 (12%)              | 22 (10%)         |
| Positive malaria RDT plus fever | 4 (2%)               | 1 (0.4%)         |
Abbreviations: RDT, rapid diagnostic test; IQR, interquartile range; \(^1\)Fever defined as tympanic temperature \(\geq 37.5^\circ C\)

### Table 2. Malaria and clinical outcomes at 14 days by treatment group

|                          | Azithromycin | Placebo | Odds Ratio (95% CI) | \(P\)-value |
|--------------------------|--------------|---------|---------------------|-------------|
| Positive malaria RDT    | 18 (8%)      | 16 (7%) | 1.17 (0.58 to 2.37) | 0.65        |
| Fever\(^1\)             | 34 (15%)     | 48 (21%)| 0.68 (0.42 to 1.11) | 0.12        |
| Positive malaria RDT and fever | 6 (3%) | 6 (3%) | 0.97 (0.31 to 3.07) | 0.96        |
| Any health center visit | 5 (2%)       | 9 (4%)  | 0.57 (0.19 to 1.72) | 0.32        |

| Reason for health center visit | Azithromycin | Placebo | Odds Ratio (95% CI) | \(P\)-value |
|--------------------------------|--------------|---------|---------------------|-------------|
| Malaria                        | 0 (0%)       | 2 (0.2%)| N/A                 | N/A         |
| Pneumonia                      | 0 (0%)       | 0 (0%)  | N/A                 | N/A         |
| Diarrhea                       | 3 (0.3%)     | 3 (1%)  | 3.00 (0.31 to 28.84) | 0.34        |

Abbreviations: RDT, rapid diagnostic test; CI, confidence interval; \(^1\)Fever defined as tympanic temperature \(\geq 37.5^\circ C\)

### Table 3. Adverse events at 14 days by treatment group

|                                | Azithromycin | Placebo | Odds Ratio (95% CI) | \(P\)-value |
|--------------------------------|--------------|---------|---------------------|-------------|
| Any adverse event              | 18 (8%)      | 29 (13%)| 0.61 (0.33 to 1.13) | 0.12        |
| Fever                          | 8 (4%)       | 19 (8%) | 0.41 (0.18 to 0.96) | 0.04        |
| Diarrhea                       | 11 (5%)      | 18 (8%) | 0.61 (0.28 to 1.33) | 0.21        |
| Vomiting                       | 6 (3%)       | 14 (6%) | 0.43 (0.16 to 1.13) | 0.09        |
| Abdominal pain                 | 2 (1%)       | 4 (2%)  | 0.51 (0.09 to 2.82) | 0.44        |
| Constipation                   | 1 (1%)       | 2 (1%)  | 0.51 (0.46 to 5.71) | 0.56        |

Abbreviations: CI, confidence interval
Figure 1

CONSORT flow diagram of study participants